TrialThe New England journal of medicine2008
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,040 papers cite itlatest 60 shown
this paperpooled ittrialcites it